Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nicotine lozenge · 1 trial · 1 indication
Proportion reporting no smoking in the 7 days prior to the 6-month follow-up timepoint and having an exhaled carbon monoxide value of less than 6 parts per million
| Arm | Type | Description |
|---|---|---|
| Electric Toothbrush | ACTIVE_COMPARATOR | Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and an electric toothbrush. |
| Nicotine Replacement Therapy | EXPERIMENTAL | Participants will receive the Ask-Advise-Refer intervention which includes an oral health practitioner asking about their tobacco use, advising them to quit smoking, and referring them to the state quitline. They will also receive a sample bag including information about smoking and oral health, the state quitline, and a two week supply of 14mg nicotine patches and 4mg lozenges. |
| Name | Type | Description |
|---|---|---|
| Ask-Advise-Refer | BEHAVIORAL | All patients will be asked if they smoke, advised to quit, and referred to the state quitline |
| Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release | DRUG | 14 mg transdermal nicotine patch |
| Nicotine lozenge | DRUG | 4mg nicotine lozenge |
Inclusion Criteria: * ≥ 18 years old * smokes at least 1 combustible cigarette per day on at least 25 days of the month Exclusion Criteria: * does not own a smartphone with internet access * myocardial infarction or stroke in the past 3 months * pregnant or breastfeeding * use of tobacco cessatio...
Nicotine lozenge is used for cigarette smoking cessation. It is an investigational small molecule being developed by National Healthcare Corp. (NHC) for this indication. The drug is currently in Phase 2 clinical development.
Nicotine lozenge is being developed by National Healthcare Corp., which trades under the ticker NHC. The company is conducting a Phase 2 clinical trial for the drug in the United States.
Nicotine lozenge is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied for its use in cigarette smoking cessation.
Nicotine lozenge is being studied in a Phase 2 clinical trial with the identifier NCT05627596, titled "Free Samples for Health." This trial is enrolling by invitation and has an enrollment of 1,200 participants in the United States.
Nicotine lozenge is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for cigarette smoking cessation. The drug has not yet completed clinical trials or received regulatory approval.